Deb Annesty

Experience

• 

  Pfizer

  May 2012 - now

  Effectively manage a portfolio of pharmaceutical products in the categories of IV Iron, Thrombosis, Oncolytic Biosimiliars and sterile injectables, within the hospitals of Atlantic Canada while appreciating each hospital's unique ecosystem. Support the creation of established clinical pathways within the hospital environment. Responsible for gaining individual hospitals as well as regional and provincial health authority formulary listings. Through a consultative approach, provide support for key customers KPIs while appreciating the financial drivers within the hospital environment and their impact on patients, healthcare professionals and healthcare institutions. From a perspective of customer-centricity and collaboration, responsible for managing partnerships with key and strategic Atlantic Canada hospitals. Support institutional quality improvement initiatives to advance patient care and treatment outcomes in identified disease states. Show less Key factor for success have been an ability to focus and execute on core priorities while optimizing opportunities to maximize ROI and manage identified potential threats within the institutional space. Products promoted include:- Monoferric (iron isomaltoside 1000) an intravenous iron for iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy- Fragmin (dalteparin) a low molecular weight heparin with 5 clinical indications: thromboprophylaxis in conjunction with surgery, treatment of acute DVT, extended treatment of cancer associated thrombosis, VTE prophylaxis of hospitalized patients, prevention of clotting in the extra-corporeal system during hemodialysis.-Bosulif (bosutinib) for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia in adult patients with resistance or intolerance to prior TKI therapy. - Precedex (dexmedetomidine) for mild to moderate sedation of ICU ventilated patients- Inspra (eplerenone)and it's support program for Heart Failure patients -Prevnar 13 (pneumococcal conjugate vaccine) for active immunization to prevent invasive pneumococcal disease in adults over the age of 50-Zyvoxam (linezolid) for the treatment of MRSA hospital acquired pneumonia and VRE infections -VFend (voriconazole) for invasive aspergillus fungal infectionsCustomer base includes Hematologists, Oncologists, Nephrologists, Critical Care Specialists, , Hospitalists, Internal Medicine Specialists, Orthopedic Specialists, Surgeons, Infectious Disease Specialists, Medical Microbiologists, Respirologists, Pharmacy Directors, PharmD hospital staff, Pharmacy Managers, Staff Pharmacists, Clinical Unit Managers, Nurse Educators, and Oncology Patient Navigators. Show less

  • Institutional Key Account Manager

    Dec 2018 - now

  • Specialty Care Representative - Institutional Business

    May 2012 - Nov 2018